Clinical trial
Efalizumab to Treat Uveitis
NCT00280826 · National Eye Institute (NEI), NIH · Completed
Key facts
| NCT number | NCT00280826 |
|---|---|
| Title | Efalizumab to Treat Uveitis |
| Official title | Treatment of Non-Infectious Intermediate and Posterior Uveitis Associated Macular Edema With Humanized Anti-CD11a Antibody Therapy |
| Lead sponsor | National Eye Institute (NEI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Uveitis, Macular Edema |
| Intervention type | Drug |
| Interventions | Efalizumab |
| Enrollment | 6 |
| Start date | Jan 1, 2006 |
| Primary completion | Feb 1, 2009 |
| Completion | Feb 1, 2009 |
| First posted | Jan 23, 2006 |
| Last update posted | Feb 2, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: